SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients

被引：0
作者：
Osawa, Kayo [1 ]
机构：
[1] Kobe Univ, Fac Hlth Sci, Grad Sch Hlth Sci, Suma Ku, Kobe, Hyogo 6540142, Japan
来源：
PHARMACOGENOMICS | 2011年 / 12卷 / 04期
关键词：
cisplatin; ERCC1; SNP; PLATINUM-BASED CHEMOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISMS; ADJUVANT CHEMOTHERAPY; EXCISION-REPAIR; DNA-REPAIR; XPD; ASSOCIATION;
D O I：
10.2217/PGS.11.15
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：445 / 447
页数：3
相关论文
共 21 条
  • [1] Chen PC, 2000, CANCER EPIDEM BIOMAR, V9, P843
  • [2] The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis
    Chen, Sufeng
    Zhang, Jie
    Wang, Rui
    Luo, Xiaoyang
    Chen, Haiquan
    [J]. LUNG CANCER, 2010, 70 (01) : 63 - 70
  • [3] Molecular mechanism of nucleotide excision repair
    de Laat, WL
    Jaspers, NGJ
    Hoeijmakers, JHJ
    [J]. GENES & DEVELOPMENT, 1999, 13 (07) : 768 - 785
  • [4] DNA structural elements required for ERCC1-XPF endonuclease activity
    de Laat, WL
    Appeldoorn, E
    Jaspers, NGJ
    Hoeijmakers, JHJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) : 7835 - 7842
  • [5] Furuta T, 2002, CANCER RES, V62, P4899
  • [6] Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
    Isla, D
    Sarries, C
    Rosell, R
    Alonso, G
    Domine, M
    Taron, M
    Lopez-Vivanco, G
    Camps, C
    Botia, M
    Nuñez, L
    Sanchez-Ronco, M
    Sanchez, JJ
    Lopez-Brea, M
    Barneto, I
    Paredes, A
    Medina, B
    Artal, A
    Lianes, P
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (08) : 1194 - 1203
  • [7] DNA Repair Gene Polymorphisms Predict Favorable Clinical Outcome in Advanced Non-Small-Cell Lung Cancer
    Kalikaki, Aristea
    Kanaki, Maria
    Vassalou, Helen
    Souglakos, John
    Voutsina, Alexandra
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    [J]. CLINICAL LUNG CANCER, 2009, 10 (02) : 118 - 123
  • [8] Mechanisms of resistance to cisplatin
    Kartalou, M
    Essigmann, JM
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2001, 478 (1-2) : 23 - 43
  • [9] Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Le Chevalier, T
    Arriagada, R
    Le Péchoux, C
    Grunenwald, D
    Dunant, A
    Pignon, JP
    Tarayre, M
    Abratt, R
    Arriagada, R
    Bergman, B
    Gralla, R
    Grunenwald, D
    Le Chevalier, T
    Orlowski, T
    Papadakis, E
    Pinel, MIS
    Araujo, C
    Della Torre, H
    de Solchaga, MM
    Abdi, E
    Blum, R
    Ball, D
    Basser, R
    De Boer, R
    Bishop, J
    Brigham, B
    Davis, S
    Fox, D
    Richardson, G
    Wyld, D
    Pirker, R
    Humblet, Y
    Delaunois, L
    Van Meerbeeck, JP
    Germonpre, P
    Vansteenkiste, J
    Nackaerts, K
    Pinel, MIS
    Vauthier, G
    Younes, RN
    Arriagada, R
    Baeza, R
    Carvajal, P
    Kleinman, S
    Orlandi, L
    Castro, C
    Godoy, J
    Kosatova, K
    Gaafar, R
    Azarian, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) : 351 - 360
  • [10] Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
    Li, Fan
    Sun, Xinchen
    Sun, Ning
    Qin, Shukui
    Cheng, Hongyan
    Feng, Jifeng
    Chen, Baoan
    Cheng, Lu
    Lu, Zuhong
    Ji, Jiazhong
    Zhou, Yingfeng
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (05): : 489 - 494
123